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This Editorial highlights a study by Colvin et al. (2017) in the current issue of Journal of 
Neurochemistry, in which the authors describe the development and characterisation of a new rabbit 
antibody (termed antibody St. Louis; AbSL) that preferentially recognizes amyloid-β (Aβ) protein 42 
(Aβ42) protofibrils over other Aβ species. Two antisera were raised against isolated Aβ42 protofibrils, 
which had similar immunochemical characteristics. In an indirect enzyme-linked immunosorbent 
assay (ELISA), the AbSL antibody displayed stronger reactivity with protofibrils than with monomers 
or fibrils and higher affinity to Aβ42 than to Aβ40. AbSL shoved very low reactivity with amyloid 
precursor protein (APP) in immunoblots of brain samples. Sandwich and competition ELISAs 
indicated that the main epitope recognised by the AbSL antibody included the N-terminal region of 
Aβ42 protofibrils. The new conformation specific antibody to Aβ42 protofibrils have research, 
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Slow and initially asymptomatic onset of neurodegenerative disorders, such as Alzheimer’s disease, 
requires clear understanding of the underlying molecular and cellular processes occurring during 
early stages of the disease. The accumulation and aggregation of Aβ peptides is a key feature of 
Alzheimer’s disease and implicated in neurotoxicity (Ugalde et al. 2016). It is now widely recognised 
that Aβ aggregates are formed through a multistep process, which involves a series of 
conformational changes before fibrils are produced. A complex and dynamic equilibrium exists 
between soluble monomers, oligomers and various insoluble aggregates (Fig. 1). Better 
understanding of this process requires the identification of intermediate states, such as Aβ 
protofibrils, which are formed during the transition from monomeric proteins to fibrils. Aβ protofibrils 
are identified as short flexible fibrils (up to 100-200 nm long with a 4-10 nm in diameter; Walsh et al. 
1999). Previous studies implicated Aβ protofibrils as pathogenic agents (Klyubin et al. 2012) and 
they have been considered as target for immunotherapy in Alzheimer’s disease (Lannfelt et al. 2014). 
Therefore, the identification and structural characterisation of Aβ protofibrils is a potentially important 
step towards understanding the mechanism of neurodegeneration in Alzheimer’s disease and other 
neurological disorders (Abu Hamdeh et al. 2017). 
 
There is a need for better Alzheimer’s disease biomarkers that are suitable for the monitoring of 
disease progression and responses to treatment (Golde 2016). As soluble Aβ oligomers and 
protofibrils have been implied to be causatives for Alzheimer’s disease, they are potentially good 
biomarker candidates. Due to their selectivity, conformation-specific antibodies are currently the best 
tools for the detection of particular transient states of Aβ in Alzheimer’s disease. These antibodies 
may also enable the development of highly targeted immunotherapeutic interventions (Westwood 
and Lawson 2015). Indeed, there are a number of antibody-based immunotherapies targeting Aβ 
currently in clinical trials (Westwood and Lawson 2015; Cummings et al. 2017) and this approach 
could be improved by immunoreagents that are selective for a particular Aβ conformation. 
 
In the study by Colvin et al. (2017), Aβ42 protofibrils were isolated by size exclusion chromatography 
(Paranjape et al. 2013) and used for the immunisation of rabbits. The selectivity of the obtained 
antisera (AbSL) were characterised using an indirect ELISA and dot blot assay with different forms 
of Aβ42 and Aβ40, including protofibrils, monomers and fibrils (Fig. 1). Significant selectivity was 
observed by AbSL antisera for protofibrils compared to monomers and fibrils at lower mass amounts 
of Aβ42. Using protein samples from C57BL/6 wild-type, amyloid precursor protein (APP) knockout 
(APP-/-; Zheng et al. 1995), and mutant APP/presenilin (APP/PS1; Jankowsky et al. 2004) mice with 
control anti-APP [22C11 (RRID AB_827115, Millipore), Y188 (RRID AB_2289606, Abcam] and anti-
Aβ [4G8 (RRIDAB_662812, Biolegend), 6E10 (RRID AB_1977025, Biolegend)] antibodies, it was 
established that the AbSL antiserum: (i) does not bind to APP, (ii) it is Aβ conformation selective, (iii) 
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recognises distinct pathological features in APP/PS1 brain tissue (Colvin et al. 2017). Epitope 
competition between AbSL and other Aβ antibodies (anti-Aβ1-16 monoclonal antibodies Ab9 and 
Ab5, from Mayo Clinic College of Medicine) revealed that the AbSL conformational epitope and the 
Ab9/Ab5 linear sequence epitope were distinct, but with some potential overlap in the N-terminal 
region. Direct and indirect sandwich ELISA using the Ab2.1.3 C-terminal Aβ42-selective antibody 
(Kukar et al. 2005) confirmed that the protofibril epitope for AbSL does not overlap with the C-
terminal end of Aβ42 (Colvin et al. 2017). 
 
While the epitope recognised by AbSL has not been identified precisely, it is clear that this antibody 
preferentially interacts with Aβ42 protofibrils (Colvin et al. 2017). Therefore, the new antibody, in 
combination with other previously developed immunoreagents to other forms of Aβ (Westwood and 
Lawson 2015), will be useful for detecting Aβ42 protofibril formation in Alzheimer’s disease as well 
as distinguishing between different forms of Aβ42. This study supports the notion that there are 
significant structural differences between Aβ protofibrils and other Aβ oligomers which can be 
detected with conformational epitope-specific antibodies. A systematic identification of amino acids 
that form the conformational epitope of AbSL in combination with the recently established fibril 
structure of Aβ1-42 (Gremer et al. 2017) would provide further information about Aβ protofibril 
structures. This information would be beneficial for the development of new diagnostics and 
therapeutics for Alzheimer’s disease. 
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Fig. 1. The AbSL antibody preferentially interacts with Aβ42 protofibrils (Colvin et al. 2017). 
Schematic representation illustrates the Aβ aggregation process initiated by misfolded, monomeric 
proteins, which undergo several conformational transitions and aggregation before they reach 


















Conformational antibody-based therapeutic opportunity
